Neuroleptics and quality of life: A patient survey;Neuroleptika und lebensqualitat: Ergebnisse einer patientenbefragung

Psychiatrische Praxis

Volumn 27, Issue 2, 2000, Pages 64-68

  Angermeyer, Matthias C ^a   Matschinger, Herbert ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ANTICHOLINERGIC EFFECT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; CHRONIC DISEASE; EPIDEMIOLOGY; GERMANY; MIDDLE AGED; QUESTIONNAIRE; STATISTICS;

ADULT; ANTIPSYCHOTIC AGENTS; BIAS (EPIDEMIOLOGY); CHRONIC DISEASE; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; SAMPLING STUDIES; SCHIZOPHRENIA;

EID: 0033624925     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Davis JM. Overview: Maintenance therapy in psychiatry. I. Schizophrenia. Am. J. Psychiatry 1975; 132: 1237-1245
2. Green MF, Marshall BD, Wirshing WC et al.. Does risperidone improve verbal working memory in treatment resistant schizophrenia? Am. J. Psychiatry 1997; 154: 799-804
3. Möller HJ, Müller H, Bovison RL, Schooler NR, Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur. Arch Psychiatry Clin. Neurosci. 1995; 245: 45-49
4. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry 1997; 154: 466-474
5. Zimbroff DJ, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Terri BS, Sebree B, Wallin BA, Kashkin KB. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am. J. Psychiatry 1997; 154: 782-791
6. Gerlach J, Peacock L. New antipsychotics: the present status. Int. Clin. Psychopharmacology 1995; 10 (Suppl. 3): 39-48
7. Kerwin RW. The new atypical antipsychotics. Br. J. Psychiatry 1994; 164: 141-148
8. Angermeyer MC, Holzinger A, Matschinger H. Lebensqualität, das bedeutet für mich... Ergebnisse einer Umfrage bei schizophrenen Patienten. Psychiat. Prax. 1999; 26: 56-60
9. Holzinger A, Angermeyer MC, Matschinger H. Lebensqualität für schizophrene Patienten - das ist... Ergebnisse einer Umfrage bei Psychiatern. Psychiat. Prax. 1997; 24: 61-64
10. Angermeyer MC. Symptomfreiheit oder Lebensqualität: Ziele der Schizophreniebehandlung. In: Katschnig H, König P (Hrsg): Schizophrenie und Lebensqualität. Wien, New York: Springer, 1994: 66-80
11. Browne S, Roe M, Laue A, Gervin M et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr. Scand. 1996; 94: 118-124
12. Kemmler G, Meise U, Tasser A, Liensberger D, Schifferle I, Braitenberg M, Schwitzer J, Hinterhuber H. Subjektive Lebensqualität schizophren Erkrankter. Psychiat. Prax. 1999; 26: 9-15
13. Boitz K, Angermeyer MC, Löffler W, Müller P, Priebe S. ,Lieber dick und geistig da...". Patienten beurteilen Clozapin. Psychiat. Prax. 1999; 26: 188-193
14. Angermeyer MC, Boitz K, Löffler W, Müller P, Priebe S. Clozapin im Urteil der Angehörigen. Psychiat. Prax. 1999; 26: 181-187